A Cost-Effectiveness Analysis of Sotorasib As Second-Line Treatment for Patients With KRAS-G12C-Mutated Metastatic Non-Small Cell Lung Cancer (mNSCLC) in Switzerland. Swiss Med Wkly 2025, 155 (1), 3777. https://doi.org/10.57187/s.3777.